
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate Inc operates within a growing ADHD medication market, which has experienced a consistent annual growth rate of approximately 8% since 2010, culminating in total sales of around $18 billion in 2020. The company has also reported positive topline results from its CTx-1301 clinical trials, indicating a beneficial treatment effect compared to placebo, thereby enhancing its pipeline potential. This combination of market growth and favorable clinical data suggests a robust upside opportunity for Cingulate, factoring in both high risks and the potential for significant rewards.
Bears say
Cingulate Inc. reported a net loss of $4.8 million, translating to an earnings per share (EPS) of $(1.09), which was below both the company's estimates and analyst consensus. Additionally, previous losses reached $7.3 million, indicating a consistent trend of underperformance relative to expectations for EPS. Key risks impacting the company's financial outlook include liquidity concerns, potential failure of product candidates in clinical trials, regulatory hurdles, commercialization challenges, and unpredictable investor sentiment in the biotech sector.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares